Perpetual Observational Study - Ventilator Associated Pneumonia
Launched by EUROPEAN CLINICAL RESEARCH ALLIANCE FOR INFECTIOUS DISEASES (ECRAID) · Feb 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Perpetual Observational Study on Ventilator-Associated Pneumonia (POS-VAP) is designed to better understand and prepare for future research on a serious lung infection that can occur in patients who are on mechanical ventilation in the Intensive Care Unit (ICU). This infection, called Ventilator-Associated Pneumonia (VAP), can lead to longer hospital stays, increased costs, and a higher risk of complications. The main goal of this study is to create a network of ICUs that can effectively conduct clinical trials to find ways to prevent or treat VAP.
To be eligible for this study, participants need to be at least 18 years old and expected to be on a ventilator for more than 48 hours while in the ICU. They must either give their own consent or have a legal representative provide consent on their behalf. Participants in this study will help researchers gather important information about VAP, which could lead to better treatments in the future. It's important to note that if a patient is not expected to recover during their hospital stay, they may not be eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Age≥18 years
- * At risk of acquiring VAP during ICU stay, defined as:
- • Requiring admission or being admitted to the ICU.
- • Expected or documented to be under IMV for more than 48 hours.
- • Consent, either a written informed consent given by the study patient in full medical, psychological, cognitive, social or legal capacity to give an informed consent, or, if not possible, by a Legally Authorized Representative of the study patient OR any applicable locally accepted form of consent OR consent waiver allowing data collection and sharing of data according to ECRAID's principles
- Exclusion Criteria:
- • Death is deemed to be imminent or inevitable during this hospital admission AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.
About European Clinical Research Alliance For Infectious Diseases (Ecraid)
The European Clinical Research Alliance for Infectious Diseases (ECRAID) is a collaborative initiative dedicated to advancing clinical research in the field of infectious diseases across Europe. ECRAID aims to enhance the efficiency and effectiveness of clinical trials by fostering partnerships among academic institutions, healthcare providers, and industry stakeholders. Through a robust network and innovative methodologies, ECRAID seeks to facilitate the rapid development and implementation of clinical studies that address critical public health challenges posed by infectious diseases. By prioritizing patient-centric approaches and data-sharing practices, ECRAID is committed to improving health outcomes and informing policy decisions in the realm of infectious disease management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Louvière, , Belgium
Leipzig, , Germany
Rijeka, , Croatia
Liège, , Belgium
Zagreb, , Croatia
Gent, Oost Vlaanderen, Belgium
Athens, , Greece
Oviedo, Asturias, Spain
Alexandroupolis, , Greece
Belgrade, , Serbia
Utrecht, , Netherlands
Praha, , Czechia
Barcelona, , Spain
Córdoba, Cordoba, Spain
Tours, , France
Edinburgh, , United Kingdom
Burjassot, Valencia, Spain
Bucharest, , Romania
Bruxelles, , Belgium
Deventer, , Netherlands
Tirana, , Albania
Dijon, , France
Le Mans, , France
Lille, , France
Limoges, , France
Tours, , France
Bucharest, , Romania
Ottignies Louvain La Neuve, , Belgium
Slavonski Brod, , Croatia
Vinohrady, , Czechia
Chalon Sur Saône, , France
Dijon, , France
Le Mans, , France
Lille, , France
Limoges, , France
Athens, , Greece
Larissa, , Greece
Roma, , Italy
Cambridge, , United Kingdom
Newcastle, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials